Theoretical Evaluation of Twenty Cannabinoid Derivatives on Androgen Receptor or 5α-Reductase Enzyme
January 2023
in “
Clinical cancer investigation journal
”
Studysummary This theoretical study suggests that certain cannabinoid derivatives could potentially be effective as androgen receptor and 5α-reductase enzyme inhibitors, indicating they may be promising candidates for prostate cancer treatment based on their higher affinity to target proteins compared to standard drugs.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The theoretical research evaluated the interaction of twenty cannabinoid derivatives with either androgen receptor or 5a-reductase enzyme. The results showed that cannabinoid derivatives 6, 13, 16, and 20 had higher affinity for the androgen receptor surface compared to testosterone, dihydrotestosterone, and flutamide. Additionally, cannabinoid derivatives 1, 3, 14, and 18 showed higher affinity for the 5a-reductase enzyme compared to dutasteride and finasteride. This suggests that these cannabinoid derivatives could act as androgen receptor inhibitors and 5a-reductase enzyme inhibitors, making them potential candidates for the treatment of prostate cancer.
